{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T08:07:49Z","timestamp":1747901269776},"reference-count":19,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["patient-research.elsevier.com","clinicalimaging.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Imaging"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.clinimag.2014.04.014","type":"journal-article","created":{"date-parts":[[2014,5,6]],"date-time":"2014-05-06T19:03:47Z","timestamp":1399403027000},"page":"724-726","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Diffusion restriction in a non-enhancing metastatic brain tumor treated with bevacizumab \u2014 recurrent tumor or atypical necrosis?"],"prefix":"10.1016","volume":"38","author":[{"given":"Lakshmanan","family":"Sivasundaram","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saman","family":"Hazany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naveed","family":"Wagle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Zada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas C.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Lerner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John L.","family":"Go","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"D'Amore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Law","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark S.","family":"Shiroishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.clinimag.2014.04.014_bb0005","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1215\/15228517-2008-010","article-title":"What is the risk of intracranial bleeding during anti-VEGF therapy?","volume":"10","author":"Carden","year":"2008","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.clinimag.2014.04.014_bb0010","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s004150070128","article-title":"Angiogenesis in malignant primary and metastatic brain tumors","volume":"247","author":"Reijneveld","year":"2000","journal-title":"J Neurol"},{"key":"10.1016\/j.clinimag.2014.04.014_bb0015","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1345\/aph.1L030","article-title":"Bevacizumab: a treatment option for recurrent glioblastoma multiforme","volume":"42","author":"Buie","year":"2008","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clinimag.2014.04.014_bb0020","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.surneu.2007.06.029","article-title":"The effect of bevacizumab (Avastin) on neuroimaging of brain metastases","volume":"70","author":"Mathews","year":"2008","journal-title":"Surg Neurol"},{"key":"10.1016\/j.clinimag.2014.04.014_bb0025","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1038\/bjc.2012.415","article-title":"Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients","volume":"107","author":"Reardon","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clinimag.2014.04.014_bb0030","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/j.jocn.2011.12.028","article-title":"A meta-analysis of bevacizumab alone and in combination with irinotecan in the treatment of patients with recurrent glioblastoma multiforme","volume":"19","author":"Zhang","year":"2012","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.clinimag.2014.04.014_bb0035","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/nm0901-987","article-title":"Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy","volume":"7","author":"Jain","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/j.clinimag.2014.04.014_bb0040","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1186\/1471-2407-9-444","article-title":"Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme","volume":"9","author":"Verhoeff","year":"2009","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.clinimag.2014.04.014_bb0045","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1200\/JCO.2009.25.0233","article-title":"Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab","volume":"28","author":"Gerstner","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinimag.2014.04.014_bb0050","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.3174\/ajnr.A2479","article-title":"Isolated diffusion restriction precedes the development of enhancing tumor in a subset of patients with glioblastoma","volume":"32","author":"Gupta","year":"2011","journal-title":"Am J Neuroradiol"},{"key":"10.1016\/j.clinimag.2014.04.014_bb0055","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11060-009-0098-8","article-title":"Bevacizumab-induced diffusion-restricted lesions in malignant glioma patients","volume":"99","author":"Rieger","year":"2010","journal-title":"J Neurooncol"},{"key":"10.1016\/j.clinimag.2014.04.014_bb0060","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.3174\/ajnr.A3053","article-title":"Persistent diffusion-restricted lesions in bevacizumab-treated malignant gliomas are associated with improved survival compared with matched controls","volume":"33","author":"Mong","year":"2012","journal-title":"Am J Neuroradiol"},{"issue":"2","key":"10.1016\/j.clinimag.2014.04.014_bb0065","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.mric.2013.02.004","article-title":"Posttreatment evaluation of central nervous system gliomas","volume":"21","author":"Shiroishi","year":"2013","journal-title":"Magn Reson Imaging Clin N Am"},{"issue":"3","key":"10.1016\/j.clinimag.2014.04.014_bb0070","doi-asserted-by":"crossref","first-page":"W495","DOI":"10.2214\/AJR.12.9544","article-title":"Perfusion MRI: the five most frequently asked clinical questions","volume":"201","author":"Essig","year":"2013","journal-title":"AJR Am J Roentgenol"},{"issue":"4","key":"10.1016\/j.clinimag.2014.04.014_bb0075","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/nrclinonc.2009.14","article-title":"VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer","volume":"6","author":"Gerstner","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"10.1016\/j.clinimag.2014.04.014_bb0080","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1097\/WCO.0b013e328332363e","article-title":"Pseudoprogression and pseudoresponse in the treatment of gliomas","volume":"22","author":"Brandsma","year":"2009","journal-title":"Curr Opin Neurol"},{"issue":"1","key":"10.1016\/j.clinimag.2014.04.014_bb0085","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s00259-012-2251-4","article-title":"Response assessment of bevacizumab in patients with recurrent malignant glioma using [(18)F]fluoroethyl-l-tyrosine PET in comparison to MRI","volume":"40","author":"Galldiks","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"10.1016\/j.clinimag.2014.04.014_bb0090","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/nrclinonc.2011.58","article-title":"The biology of brain metastases\u2014translation to new therapies","volume":"8","author":"Elchler","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.clinimag.2014.04.014_bb0095","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1172\/JCI45758","article-title":"Charting the course across the blood-brain barrier","volume":"121","author":"Nathanson","year":"2011","journal-title":"J Clin Invest"}],"container-title":["Clinical Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0899707114001156?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0899707114001156?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,10]],"date-time":"2019-08-10T07:30:30Z","timestamp":1565422230000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0899707114001156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S0899707114001156"],"URL":"https:\/\/doi.org\/10.1016\/j.clinimag.2014.04.014","relation":{},"ISSN":["0899-7071"],"issn-type":[{"value":"0899-7071","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diffusion restriction in a non-enhancing metastatic brain tumor treated with bevacizumab \u2014 recurrent tumor or atypical necrosis?","name":"articletitle","label":"Article Title"},{"value":"Clinical Imaging","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinimag.2014.04.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}